MIGNAR 50 MF 10

About

MIGNAR 50 MF is a fixed-dose combination medication containing Vildagliptin and Metformin, prescribed for the management of Type 2 Diabetes Mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones, GLP-1 and GIP, which in turn enhance insulin secretion from pancreatic beta cells and suppress glucagon secretion from alpha cells, particularly in a glucose-dependent manner. This mechanism helps to reduce post-meal and fasting blood glucose levels without a high risk of hypoglycemia.

Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. The synergistic action of Vildagliptin and Metformin provides comprehensive glycemic control, addressing multiple pathophysiological defects in Type 2 Diabetes. This combination is typically used when diet and exercise alone, or monotherapy with either Vildagliptin or Metformin, do not achieve adequate glycemic targets.

Uses

• Management of Type 2 Diabetes Mellitus in adults.
• Improvement of glycemic control as an adjunct to diet and exercise.
• When monotherapy with Metformin or Vildagliptin is insufficient.
• To reduce fasting and post-prandial blood glucose levels.

Directions For Use

Take orally with meals, usually once or twice daily, as directed by a physician. Swallow the tablet whole with water, do not crush or chew.

Benefits

• Effective in lowering blood glucose and HbA1c levels.
• Provides dual mechanism of action for comprehensive control.
• Lower risk of hypoglycemia compared to sulfonylureas.
• May contribute to modest weight stabilization or reduction.
• Improves insulin sensitivity and pancreatic beta-cell function.
• Convenient fixed-dose combination for improved adherence.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Dizziness
• Fatigue
• Nasopharyngitis
• Tremor
• Hypoglycemia (rare, especially when used alone)
• Lactic acidosis (rare, serious with Metformin)
• Pancreatitis (rare, with Vildagliptin)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis, a rare but serious side effect of Metformin.
• Pregnancy - Generally not recommended during pregnancy. Consult a doctor to weigh potential risks and benefits, and discuss alternative treatments.
• Breastfeeding - Not advised during breastfeeding as components may pass into breast milk. Seek medical advice for safer alternatives.
• Liver - Use with caution in patients with liver impairment. Metformin is contraindicated in severe hepatic dysfunction due to increased risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dosage adjustment may be required for moderate impairment.
• Lung - Use with caution in conditions causing hypoxia (e.g., severe lung disease) as it may increase the risk of lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.